In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 25, No. 18_suppl ( 2007-06-20), p. 1082-1082
Abstract:
1082 Background: This study was performed to evaluate retrospectively the efficacy and tolerance of gemcitabine plus oxaliplatin (GEMOX) as salvage chemotherapy in patients with metastatic breast cancer (MBC) in a mono-institutional series. Methods: From January 2003 to March 2005, 38 MBC patients were treated at disease progression according to three schedules: (a) gemcitabine 1000 mg/m 2 on day 1 and 8 and oxaliplatin 100 mg/m 2 on day 1 every three weeks (n=30); (b) gemcitabine 1,000 mg/m 2 on day 1, followed same day by oxaliplatin 100 mg/m 2 every two weeks (n=7); (c) gemcitabine 1250 mg/m 2 on days 1 and 8 and oxaliplatin 100 mg/m 2 on day 1 every four weeks (n=1). Results: All patients (median age, 58 years) received prior chemotherapy for metastatic disease (median of four lines). Radiological response was assessed in 36 patients: 12 patients (33%) experienced a partial response and 11 patients (31%) had a stable disease. The median times to progression and survival were 4 months (range, 0–21 months) and 10 months (range, 2–24 months), respectively. A total of 233 cycles were administered with a median of 5.5 cycles per patient (range, 1–21 cycles). Grade 3/4 toxicity consisted of myelotoxicity in 26% of patients and neurotoxicity in 8%. Conclusions: This retrospective study suggests that GEMOX is an effective combination with a good tolerance profile in heavily pretreated MBC. Further evaluation of this regimen is warranted in this tumor indication. No significant financial relationships to disclose.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2007.25.18_suppl.1082
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2007
detail.hit.zdb_id:
2005181-5
Permalink